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Abstract
Purpose The SP142 PD-L1 assay is a companion diagnostic for atezolizumab in metastatic triple-negative breast cancer 
(TNBC). We strove to understand the biological, genomic, and clinical characteristics associated with SP142 PD-L1 posi-
tivity in TNBC patients.
Methods Using 149 TNBC formalin-fixed paraffin-embedded tumor samples, tissue microarray (TMA) and gene expres-
sion microarrays were performed in parallel. The VENTANA SP142 assay was used to identify PD-L1 expression from 
TMA slides. We next generated a gene signature reflective of SP142 status and evaluated signature distribution according 
to TNBCtype and PAM50 subtypes. A SP142 gene expression signature was identified and was biologically and clinically 
evaluated on the TNBCs of TCGA, other cohorts, and on other malignancies treated with immune checkpoint inhibitors (ICI).
Results Using SP142, 28.9% of samples were PD-L1 protein positive. The SP142 PD-L1-positive TNBC had higher CD8+ T 
cell percentage, stromal tumor-infiltrating lymphocyte levels, and higher rate of the immunomodulatory TNBCtype compared 
to PD-L1-negative samples. The recurrence-free survival was prolonged in PD-L1-positive TNBC. The SP142-guided gene 
expression signature consisted of 94 immune-related genes. The SP142 signature was associated with a higher pathologic 
complete response rate and better survival in multiple TNBC cohorts. In the TNBC of TCGA, this signature was correlated 
with lymphocyte-infiltrating signature scores, but not with tumor mutational burden or total neoantigen count. In other 
malignancies treated with ICIs, the SP142 genomic signature was associated with improved response and survival.
Conclusions We provide multi-faceted evidence that SP142 PDL1-positive TNBC have immuno-genomic features character-
ized as highly lymphocyte-infiltrated and a relatively favorable survival.
Keywords Triple-negative breast cancer · SP142 PD-L1 · Tumor-infiltrating lymphocytes · Immune-check point inhibitors
Introduction
The prognosis of triple-negative breast cancer (TNBC) 
patients remains inferior to other clinical subtypes of breast 
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which can be targeted by endocrine therapy or anti-HER2 
therapy [1]. Recent studies have revealed that TNBC has 
more immunogenomic features including increased tumor-
infiltrating lymphocytes (TILs), increased expression of 
immune-related molecules and signatures, and higher tumor 
mutational burden (TMB), amongst mammary malignancies 
[2, 3]. Therefore, targeting programmed death 1 (PD-1) or 
its ligand (PD-L1), in combination with chemotherapy, is an 
emerging approach to offer clinical benefits in both early and 
advanced TNBC [4–9].
Among recent breast cancer trials with immune targeting 
drugs, the IMPASSION-130 trial demonstrated that the anti-
PD-L1 monoclonal antibody atezolizumab plus nab-pacli-
taxel prolonged progression-free survival (PFS) in patients 
with metastatic TNBC [5]. Furthermore, the researchers 
showed that overall survival (OS) was improved by add-
ing atezolizumab in the PD-L1-positive subgroup, which 
was defined by PD-L1 expression on immune cells using 
the SP142 antibody-based immunohistochemistry assay. 
Based on these findings, the Food and Drug Administra-
tion approved the use of atezolizumab for patients with PD-
L1-positive metastatic TNBC [10], with the SP142 PD-L1 
assay as a companion diagnostic. In addition, a clinical trial 
conducted in patients with early TNBC showed that PD-
L1-positivity was a strong predictor for pathological com-
plete response (pCR) [11].
These findings led us to investigate the clinical 
and genomic characteristics associated with SP142 
PD-L1+ TNBC, with the hypothesis that PD-L1 protein 
expression might be associated with better survival out-
come in the absence of immunotherapies. In this study, 
we evaluated PD-L1 expression by SP142 assay on TNBC 
tissue microarray (TMA), investigated clinicopathological 
features of PD-L1+ cases, and performed genomic analyses 
to develop a SP142 gene expression signature. Clinical and 
genomic aspects of this signature were further assessed in 
The Cancer Genome Atlas (TCGA) [12] and other TNBC 
cohorts. Finally, we tested the SP142 signature in the cohorts 




The institutional review board (IRB) of Gangnam Sever-
ance Hospital, Yonsei University, Seoul, Korea, approved 
the study in accordance with good clinical practice guide-
lines and the Declaration of Helsinki (local IRB approval 
number: 3-2013-0268). The need for informed consent was 
waived because of the retrospective design.
Patients and tumor samples
Formalin-fixed paraffin-embedded (FFPE) TNBC tumor 
samples were selected from the database of breast cancer 
patients treated between January 1999 and December 2014 
at Gangnam Severance Hospital, Yonsei University Medi-
cal College, Seoul, Korea. Tumor cellularity was defined 
as the percentage of invasive tumor nuclei and was over 
80% in all breast cancer specimens. Exclusion criteria for 
patient samples included: samples only exhibiting in situ 
carcinoma of the breast, bilateral breast cancers, as well 
as non-epithelial origin breast cancer, such as phyllodes 
tumor, sarcoma, or lymphoma.
TNBC was defined by the lack of ER, PR and HER2 
based on immunohistochemical (IHC) stain. For routine 
IHC studies, ER (1:100 clone 6F11; Novocastra, Newcas-
tle upon Tyne, UK), PR (clone 16; Novocastra), HER2 
(4B5 rabbit monoclonal antibody; Ventana Medical 
Systems, Tucson, AZ, USA), and Ki-67 (MIB-1; Dako, 
Glostrup, Denmark) were stained using formalin-fixed 
paraffin-embedded tissue sections as previously described 
[13, 14]. ER positivity and PR expression on immunohis-
tochemistry were defined according to the modified Allred 
system. In our study, ER and PR positivity were defined as 
an Allred score ≥ 3. The HER2 status was considered posi-
tive with a score of 3+ and negative with a score of 0 or 
1+ [15]. Tumors with a score of 2+ were sent for fluores-
cent in situ hybridization analysis according to the proto-
col given by the supplier (PathVysion kit; Vysis, Downers 
Grove, IL, USA or HER2 inform; Ventana). A total of 149 
TNBC subjects were investigated in our study.
Tissue microarray, SP142 PD‑L1 assay, and other 
studies
TMA paraffin blocks were generated as previously 
described using an Accu Max Array tissue-arraying instru-
ment (Petagen, Inc., Seoul, Korea) [16]. In each samples, 
a single core was punched in the area showing invasive 
tumor nuclei was comprised ≥ 80% to construct the TMA 
slides. PD-L1 expression, stromal TILs, and CD8 percent-
age were assessed from TMA slides.
PD-L1 expression was determined using VENTANA 
PD-L1 SP142 assay, which is a qualitative IHC assay using 
rabbit monoclonal anti-PD-L1 clone SP142 [5, 17]. PD-L1 
protein on tumor-infiltrating immune cells was assessed in 
each TMA slide stained with OptiView DAB IHC Detec-
tion Kit and OptiView Amplification Kit on a VENTANA 
BenchMark ULTRA instrument. The scoring of PD-L1 
positivity followed the guidelines and where pathologist 
(YJC) confirmed the tumor-infiltrating immune cells which 
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were morphologically consistent with lymphocytes, mac-
rophages, dendritic cells, and granulocytes by H&E stain-
ing. Then, PD-L1 expression on tumor-infiltrating immune 
cells was quantified in intra-tumoral and peri-tumoral 
stromal area. Areas with neutrophilic debris and necrotic 
debris was excluded from scoring. Presence of discernible 
PD-L1 staining of any intensity covering ≥ 1% of tumor 
area was considered as PD-L1 positive [5, 9]. Benign ton-
sil tissue was used as a positive (lymphocytes and mac-
rophages in germinal center, reticulated crypt epithelium) 
and negative (inter-follicular lesion and overlying squa-
mous epithelium) controls. PD-L1 expression values for 
each subject are presented as Supplementary Table S1A. 
The PD-L1 SP142 assay was performed blindly with no 
clinical information being given to the examiner.
The TIL counts were measured as previously described 
[13, 18, 19]. TILs were scored according to the standardized 
methodology proposed by the international TIL Working 
Group [20]. All mononuclear cells, including lymphocytes 
and plasma cells, but not polymorphonuclear leukocytes, 
were counted. The area outside the tumor border, around the 
intraductal component, and normal lobules were excluded. 
For each case, the TIL counts were reported as a percentage. 
CD8 percentage among immune cells was obtained using 
an anti-CD8 rabbit monoclonal antibody (SP57, Ventana).
RNA extraction, Affymetrix microarray, and data 
analysis
Total RNA was isolated using Qiagen RNeasy FFPE kit 
(Qiagen, Hilden, Germany) according to the manufactur-
ers’ instructions. RNA samples extracted from FFPE tis-
sues were analyzed in terms of RNA concentration and 
purity using NanoDrop ND-1000 Spectrophotometer (Nan-
oDrop Technologies, Wilmington, DE, USA) [21]. Briefly, 
double-stranded DNA was synthesized using One-cycle 
cDNA Synthesis Kit (Affymetrix) followed by purification 
with GeneChip Sample Cleanup Module (Affymetrix). The 
double-stranded DNA was used as template for the in vitro 
transcription using Gene Chip IVT PLUS Reagent Kit 
(Affymetrix), which yields biotinylated cRNA. The purified 
biotin-labeled target cRNA was then segmented into short 
sequences. The HG-U133_Plus_2 microarrays (Affymetrix) 
were directly loaded with 200 µl of hybridization cocktail 
solution and then placed in Genechip Hybridization Oven 
640 (Affymetrix) rotating at 60 rpm at 45 °C for 16 h. After 
hybridization, the arrays were washed on Genechip Fluid-
ics Station 400 (Affymetrix) and scanned using Genechip. 
The microarray data were visually inspected for physical 
damage and background noise. Datasets of all probes were 
normalized using 100 housekeeping genes in mask files of 
U-133_Plus_2.0 to a means intensity of 2000 before further 
date processing.
The gene expression data were normalized by the quantile 
method, log2 transformed, and median centered across genes 
and samples. A hierarchical clustering analysis was carried 
out using Cluster 3.0 [22] and Java Tree View Software. 
Significance analysis of microarrays with false-discovery 
rate of 5% was used to identify SP142 PD-L1 related genes 
and gene signatures [23]. We next applied a collection of 
633 known gene signatures, representing multiple biological 
pathways and cell types, to the median centered and stand-
ardized gene expression matrix [24].
Gene expression signatures were calculated as the median 
expression of all the genes in the signature as published [25]. 
Univariable and multivariable analyses were performed 
using standardized signature scores in R-studio using the 
Cox regression hazard model. Heat-map and PCA plot were 
used in analysis and DAVID (The Database for Annotation, 
Visualization and Integrated Discovery) tool was used in 
functional analysis [26, 27].
TNBCtype and PAM50 assay
Our RNA dataset was uploaded in the website (http:// cbc. 
mc. vande rbilt. edu/ tnbc/) [28], and the TNBCtypes were 
obtained for each subjects [29]. For PAM50 intrinsic sub-
types, we first applied a new HER2/ER subgroup-specific 
gene normalization method [30], followed by the PAM50 
predictor [31]. For each sample, we calculated the correla-
tion coefficient to the PAM50 centroids (Basal-like, HER2-
Enriched, Luminal A, Luminal B and Normal-like signa-
tures, respectively) [32].
External gene expression data analysis
TCGA RNA-seq data were collected as previously described 
[12, 33]. Samples were limited to TNBC tumors defined by 
IHC examination. TMB, total neoantigen count, and lym-
phocyte-infiltration signature score for each subject in the 
TCGA cohort were determined from a previous publication 
[34]. RNA-seq data for NCT01560663 is published [35]. 
Microarray and variant data for the METABRIC cohort [36], 
was obtained from cBioPortal. RNA-seq data from SCAN-
B was downloaded from GEO: GSE96058 [37]. For this 
study, non-TNBC samples in METABRIC and SCAN-B 
were excluded.
In urothelial carcinoma, raw sequencing data required 
for RNA-seq analyses have been deposited to the Euro-
pean Genome-Phenome Archive under accession number 
EGAS00001002556 [38, 39]. In melanoma, the RNA-seq 
data are deposited in the European Nucleotide Archive 
(ENA) [40], under accession number PRJEB23709. For 
RNA-seq datasets, genes with no reads across any of the 
samples were removed. Raw RNA-seq data were aligned to 
reference genome hg38 and quantified using a STAR-Salmon 
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pipeline as previously described [41]. Salmon gene-level 
counts were upper quartile normalized. Genes with an aver-
age expression less than 10 were filtered from the dataset.
Statistical analyses
The distributions of non-parametric variables were com-
pared using the Mann–Whitney U test. Survival curves were 
constructed using the Kaplan–Meier product limit method 
and compared between subtypes with the log-rank test using 
open-to-public datasets for which DFS, RFS, PFS, and OS 
results are available. In the training set, the cutoff point of 
the SP142 gene signature score was obtained using the time-
dependent ROC curve. In the cohort of SCAN-B, interac-
tion tests were used to explore differential effects between 
dichotomized PD-L1-signature score status and chemother-
apy treatment in relation to OS. Cox proportional hazard 
regression model adjusted for available prognostic clinical 
covariates such as stage was performed to calculate hazard 
ratios using 95% confidence intervals. Variables showing 
a statistical significant difference in the univariate analysis 
were entered in the multivariable analysis. Survival analyses 
were performed using the R package survival. All statisti-
cal analyses were performed using the R software (https:// 
www.r- projet. org; version 3.6.1) and the GraphPad Prism. A 
P-value < 0.05 was considered statistically significant.
Data and code availability
The published article includes all datasets and code gen-
erated in this study. The dataset of 149 TNBC patients 
generated during this study are available at GEO Datasets: 
GSE135565 and GSE157284. Newly generated dataset for 
the current study are available at the NCBI GEO database 
under accession numbers GSE157284 with the following 
secure token: qjexicmuldkxjmr. To access the dataset, the 
editors or reviewers should access the GEO website (https:// 
www. ncbi. nlm. nih. gov/ geo/) and insert these secure tokens.
Results
Clinical and immunological characteristics of SP142 
PD‑L1‑positive TNBC
To begin to explore the biology and clinical associations of 
PD-L1 protein expression in TNBC, we collected a set of 
149 tumors from which we created TMAs and performed 
DNA microarray-based gene expression profiling using 
Affymetrix microarrays. Baseline characteristics of the study 
population is summarized in Supplementary Table S1B-C. 
All tumors were treatment-naïve. SP142 PD-L1 expres-
sion was successfully determined using these TMAs, and 
showing a rate of PD-L1+ tumors of 28.9% (43/149; Fig. 1a, 
Representative images in Fig. 1b).
From the DNA microarray gene expression data, we 
identified the “TNBC-Type” molecular classification [29] 
for each subject (Fig. 1c, left). When we compared “TNBC-
Types” according to PD-L1-positivity, the immunomodu-
latory subtype had the highest rate of PD-L1 positivity 
(57.1%), whereas the other subtypes had PD-L1-positiv-
ity rates of 10 to 30%. PAM50 subtypes were also evalu-
ated in relation to PD-L1 expression and although this 
comparison was not significant, all PD-L1+ subjects had 
basal-like tumors (Fig.  1c, right). Next, we noted that 
PD-L1+ TNBC had significantly higher mean CD8+ cell 
percentage than PD-L1-negative TNBC (Fig. 1d). In addi-
tion, PD-L1+ TNBC had higher average of TIL counts com-
pared to PD-L1-negative TNBC (Fig. 1e).
In survival analyses, we only included non-metastatic 
TNBCs and excluded one case with missing survival data, 
leaving 145 subjects available; most of these patients 
received adjuvant chemotherapy (95%), but none of them 
were treated with anti-PD-1/PD-L1 inhibitors. The recur-
rence-free survival (RFS) was significantly prolonged in 
TNBC patients with PD-L1+ compared to those without 
PD-L1 (Fig. 1f). In univariable analysis, stage and PD-L1 
status were significant prognostic factors (Supplementary 
Table S1D). In multivariable analysis, PD-L1+ subjects 
trended to have a better RFS compared to PD-L1-negative 
(Supplementary Table S1D).
Gene signature for SP142 PD‑L1(+) TNBC
To begin to explore the possible associations of gene expres-
sion patterns with PD-L1 protein expression, we first noted 
that mean PD-L1 mRNA expression was not significantly 
different by SP142 PD-L1 protein assay status (Fig. 2a). 
Thus, we conducted supervised analyses according to PD-L1 
protein positivity to identify a gene expression pattern asso-
ciated with SP142 PD-L1 in TNBC. A two-class signifi-
cance analysis of microarrays (SAM) [23] supervised analy-
sis identified 94 highly expressed genes in PD-L1+ TNBC 
(listed as Supplementary Table S2, expression heatmap as 
Supplementary Fig. S1). A majority of this gene cluster, 
which is henceforth referred to as SP142 signature, consisted 
of immune-related genes including immunoglobulins, major 
histocompatibility genes, and chemokines. To better under-
stand the biological functions underlying the SP142 signa-
ture, we explored the gene ontology (GO) associated with 
this 94 gene set. This analysis strongly implicated a response 
of the immune system, largely mediated through adaptive 
immunity (Supplementary Table S2). The extent of lympho-
cyte activity in PD-L1+ patients is well illustrated by a heat-
map showing expression of the 21 genes associated with the 
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GO term “lymphocyte mediated immunity (GO:0002449)” 
and PD-L1 mRNA levels (Fig. 2b).
We next calculated a SP142 signature score in our 149 
subjects and found that, as expected, the mean score was sig-
nificantly higher in PD-L1+ TNBC than in PD-L1-negative 
(Fig. 2c). Next, we tested the prognostic value of SP142 sig-
nature. The continuous SP142 signature score was prognos-
tic for RFS (HR 0.535, 95% CI 0.328–0.872) on this set of 
145 non-metastatic TNBC patients. To utilize the SP142 sig-
nature as a prognostic categorical value, the time-dependent 
receiving operating characteristic (ROC) curve in relation 
to RFS was used to identify the optimal cutoff (Supplemen-
tary Fig. S2A). As a result, the top two-thirds were selected 
for the better RFS group versus the bottom third. Biologi-
cally, cases with top two-thirds of SP142 signature score had 
higher CD8 and TIL counts than those with bottom one-third 
(Supplementary Fig. S2B-C). Based on these findings, we 
classified our patients into two groups by SP142 signature; 
top two-thirds and bottom one-third. This assignment rate 
also reflects the findings of a recent clinical trial showing the 
PD-L1-positive rate as 56% in early TNBC [11].
The top two-thirds group had a significantly higher rate of 
PD-L1+ tumors (Fig. 2d), as was expected. When survival 
analyses were performed between these groups, we found 
that patients in the top two-thirds had a superior RFS when 
compared to patients in the lowest third for SP142 signature 
(Fig. 2e). Multivariable analyses including stage further sup-
ported the independent prognostic value of SP142 signature 
(Table 1). In contrast, continuous or categorical values of 
PD-L1 mRNA levels alone were not associated with RFS in 
the same set (Supplementary Fig. S3), indicating that SP142 
signature was a better prognostic factor than PD-L1 protein 
expression in infiltrating immune cells (which only trended 
in multivariable analyses), or PD-L1 mRNA levels on this 
set.
Clinical value of SP142 signature in early TNBC
We next addressed the possible clinical value of the SP142 
signature in early TNBC with respect to pCR and survival 
outcomes. First, we used published data from a TNBC 
cohort of 93 patients undergoing preoperative docetaxel/
Fig. 1  Clinical and pathological characteristics of SP142 PD-L1-pos-
itive TNBC. a The PD-L1 positive rate according to SP142 expres-
sion was 28.9% (43 of 149). b Representative images for PD-L1-pos-
itive and -negative tumors in high-power fields (× 400 magnification). 
c Left: SP142 PD-L1 percent positivity partitioned by TNBCtype 
(immunomodulatory [IM], basal-like 1 [BL1], basal-like 2 [BL2], 
luminal-androgen receptor [LAR], mesenchymal [M], mesenchymal 
stem-like subtypes [MSL], and unspecified [UNS]). The rate of PD-
L1-positive tumors was significantly higher in the IM subtype; the 
IM subtype had the highest rate of PD-L1 positivity (57.1%), whereas 
the other subtypes had PD-L1-positivity rates of 10–30% (Chi-square 
test). Right: PD-L1-positivity rate was not significantly different 
according to the PAM50 subtype (Chi-square test). d PD-L1-posi-
tive TNBC had significantly higher mean CD8(+) percentage count 
(Mann–Whitney U test). e PD-L1-positive TNBC had higher mean of 
TIL counts compared to PD-L1-negative TNBC (Mann–Whitney U 
test). f Recurrence-free survival was significantly prolonged in PD-
L1-positve TNBC than in PD-L1-negative TNBC (log-rank test)
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Fig. 2  An RNA expression-based SP142 gene signature. a PD-L1 
mRNA expression in breast tumor samples partitioned by SP142 
PD-L1 status (Mann–Whitney U test). b A heat-map clustering breast 
tumors with 21 genes of the “Lymphocyte Mediated Immunity” sig-
nature. The rows indicate individual genes, and the columns indicate 
each sample. PD-L1 IHC status and relative PD-L1 mRNA expres-
sion are denoted for each sample above. c SP142 signature was sig-
nificantly higher in PD-L1-positive tumors (Mann–Whitney U test). 
d The proportion of PD-L1 positive patients in the top two-thirds 
SP142 signature group is significantly higher than in the bottom one-
third group (Chi-square test). e The top two-thirds SP142 signature 
group had a superior recurrence-free survival compared to the bottom 
one-third SP142 signature group (log-rank test)
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carboplatin chemotherapy (NCT01560663) [42]. The 
SP142 signature-high subset of patients had a higher pCR 
rate (Fig. 3a), and when analyzed as a continuous score, 
patients with a pCR had a significantly higher SP142 scores 
(Fig. 3b). These findings suggest that a high SP142 signature 
might be associated with a higher likelihood of response to 
neoadjuvant chemotherapy in TNBC.
To test a relationship between SP142 signature and adju-
vant chemotherapy responsiveness, we used RNA sequenc-
ing data in TNBC samples from the Sweden Cancerome 
Analysis Network-Breast Initiative (SCAN-B) cohort 
[37]. First, patients with higher SP142 signature had sig-
nificantly better OS (Supplementary Fig. S4A), which was 
even more significant when the patient set was limited to 
TNBC patients receiving chemotherapy (Supplementary Fig. 
S4B). When we classified the patients into four groups by 
SP142 signature and chemotherapy treatment, chemotherapy 
improved OS in the SP142 top two-thirds group whereas it 
did not for those in the SP142 signature bottom one-third 
group (Fig. 3c). The interaction test between chemotherapy 
and dichotomized SP142 signature status was significant 
(Pinteraction = 0.026), however, we acknowledge that this is 
not a randomized trial, and thus further testing is warranted.
Lastly, we evaluated the prognostic value of SP142 signa-
ture in another non-metastatic TNBC cohort from Molecu-
lar Taxonomy of Breast Cancer International Consortium 
(the METABRIC cohort) [37]. In this patient subset, both 
disease-free survival (DFS) and OS were superior in the 
SP142 signature top two-thirds group than in the lowest third 
group (Fig. 3d, e).
Immunologic characterization for SP142 signature 
using TCGA 
Next, we applied the SP142 signature to TNBC from TCGA. 
We divided tumors into two groups as the top two-thirds 
and bottom third using SP142 signature. We compared lym-
phocyte infiltration-signature score [43] between these two 
group, revealing that lymphocyte-infiltration signature score 
(as determined by the TCGA immune Pan-Cancer analysis) 
was significantly increased in SP142 signature-high patients, 
consistent with the increased TIL counts that were noted in 
SP142 PD-L1+ TNBC (Fig. 4a). We investigated whether 
differences in somatic mutation or neoantigen burden could 
explain the differences between these patient subsets, how-
ever, neither of these measures differed between groups 
(Fig. 4a) and strong correlations were only found between 
SP142 signature and lymphocyte-infiltrating score or TMB 
and total neoantigen count (Fig. 4b).
To further validate the biological implications of the 
SP142 signature, we examined the possible association of 
this signature when compared to 633 previously published 
gene signatures [24, 44]. Using SAM analysis provided addi-
tional evidence of the strong association between the SP142 
gene signature and an active immune response where we 
found 12 immune pathway-enriched signatures with at least 
fourfold increase in the SP142 signature top two-thirds sam-
ples (Fig. 4c and Supplementary Table S3).
SP142 signature in other malignancies treated 
with ICIs
SP142 is an assay used to select cancer patients to receive 
immune checkpoint inhibitors, and given that no publically 
available TNBC ICI-treated data set exists, we turned to 
other tumor types to evaluate the relationship between the 
SP142 signature and ICI responsiveness. First, we tested our 
gene signature on a metastatic urothelial carcinoma cohort 
treated with atezolizumab [38, 39]. Comparison of mean 
SP142 signature by response to atezolizumab found that 
patients that experienced a complete response (CR) showed 
the highest score (Fig. 5a). Also, in the group with top one-
third SP142 signature, the CR rate was higher, and the rate 
of progressive disease (PD) was lower, than in either the 
middle or bottom one-third groups (Fig. 5b).
In this cohort, PD-L1 expression on immune cells 
(IC) was assessed by the SP142 assay, which is identi-
cal to the assay used in our 149 TNBCs, though the 
urothelial carcinoma cohort was score as IC0 (< 1%), IC1 
(≥ 1% and < 5%), or IC2/3 (≥ 5%). The SP142 signature 
Table 1  The Cox regression 
hazard model with SP142 
signature and stage
Recurrence-free survival
HR 95% CI P HR 95% CI P
SP142 signature 0.026
Continuous
0.546 0.321–0.930 Bottom one 1 0.049
Top two 0.463 0.215–0.996
Stage
 I 1 I 1
 II 1.647 0.585–4.636 0.345 II 1.638 0.579–4.636 0.352
 III 7.639 2.551–22.876  < 0.0001 III 8.081 2.696–24.223  < 0.0001
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Fig. 3  Clinical value of SP142 signature in TNBC. a In the Madrid 
cohort, (NCT01560663), pathologic complete response (pCR) rate 
was higher in the SP142 signature top two-thirds group (Chi-square 
test). b SP142 signature score was significantly higher in the pCR 
group than in non-pCR group (unpaired T-test). c Overall Survival 
(OS) in TNBC from SCAN-B, with patients classified by SP142 
signature and chemotherapy treatment status., Patients in the SP142 
signature top two-thirds group that received chemotherapy had bet-
ter OS (the log-rank test). The interaction test between chemotherapy 
treatment and dichotomized SP142 signature status was significant 
(Pinteraction = 0.026). d Disease-free, and e overall survival in TNBC 
patients of the METABRIC cohort. The SP142 signature top two-
thirds group had significantly better prognosis (log-rank test)
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score showed an increasing pattern according to the 
IC groups (Fig. 5c). In survival analysis, a continuous 
SP142 signature was prognostic for OS (HR 0.815, 95% 
CI 0.699–0.951), and furthermore, the group with top 
one-third SP142 signature score showed a better OS than 
the group with bottom two-thirds (Fig. 5d).
Lastly, we evaluated our SP142 signature in a melanoma 
cohort treated with ICIs [40, 45]. This cohort consisted of 
Fig. 4  Immunologic characterization for SP142 signature in the 
TNBC of TCGA. a Left: The lymphocyte-infiltrating signature score 
was significantly higher in the top two-thirds SP142 signature group 
than in the bottom one-third group (Mann–Whitney U test). Tumor 
mutational burden (middle) and total neoantigen count (right) did not 
significantly differ between the top two-thirds and bottom one-third 
SP142 signature groups (Mann–Whitney U test). b The SP142 signa-
ture score shows strong correlation with the lymphocyte-infiltration 
score, but not with correlated with total mutation burden (TMB) or 
total neoantigen count. TMB and total neoantigen were also corre-
lated (Pearson’s R-test). The numbers in the graph indicate Spearman 
rank correlation coefficients. c Heat-map displaying immune-related 
gene signatures with > fourfold increase between SP142 signature top 
two-thirds and bottom one-third groups (SAM analysis)
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Fig. 5  SP142 signature in other malignancies treated with immune 
check-point inhibitors (ICIs). a–d In metastatic urothelial carci-
noma patients treated with atezolizumab, a SP142 signature score in 
patients partitioned by treatment response (PD progressive disease, 
SD stable disease, PR partial response, CR = complete response). The 
complete response (CR) group showed the highest mean SP142 sig-
nature score (one-way ANOVA test). b Response rates in patients 
partitioned by SP142 signature scores tertiles. The CR rate was 
higher, while PD was lower in top one-third than in either middle 
or bottom one-third groups (the Chi-square test). c SP142 signature 
score in the subsets of patients by VENTANA SP142 assay clas-
sification (IC0 = PDL1 expressing immune cells < 1%, IC1 (≥ 1% 
and < 5%), IC2/3 (≥ 5%)). SP142 score showed an increasing pat-
tern according to the IC groups (one-way ANOVA test, P < 0.001; 
unpaired T-test between IC0 and IC1, P < 0.0001; unpaired T-test 
between IC1 and IC2/3, P < 0.0001). d Overall survival (OS) of 
patients grouped with the top one-third SP142 signature score ver-
sus the bottom two-thirds (log-rank test). e, f In melanoma patients 
treated with immune-check point inhibitors, progression-free (e), and 
overall survival (f) are significantly better for the group of patients in 
the top two-thirds of SP142 signature score relative to the lowest one-
third group (log-rank test)
175Breast Cancer Research and Treatment (2021) 188:165–178 
1 3
73 patients treated with either anti-PD-1 therapy or com-
bination blockade of PD-1 and CTLA-4 (Supplementary 
Table S4A). A continuous SP142 signature was prognostic 
for both PFS and OS (Supplementary Table S4B). Further 
survival analyses showed that the top two-thirds patients 
had a superior PFS and OS compared to bottom one-third 
patients (Fig. 5e, f).
Discussion
In this study, we investigated the clinical and genomic char-
acteristics of SP142 PD-L1+ TNBC relative to SP142 PD-
L1-negative TNBC. Our findings demonstrate that SP142 
PD-L1+ tumors have more immunogenic traits, including 
high TILs by H&E, higher CD8 counts by IHC, enrichment 
of immune TNBC genomic subtype and showed elevated 
immune gene signatures at the gene expression level. Since 
several lines of evidence suggested that the SP142 assay 
detects more immune cells but fewer tumor cells compared 
to other PD-L1 assays [46, 47], and thus it is expected 
that SP142-positive TNBCs would be enriched with TILs, 
CD8+ cells, and other immune features, and they were. 
Intriguingly, PD-L1 mRNA expression level did not dif-
fer according to SP142 PD-L1 status. Despite a few earlier 
studies showing that PD-L1 mRNA was correlated with 
PD-L1 expression by SP142 assay in various malignancies 
[48–50], the recent study conducted in TNBC consistently 
showed that the levels of PD-L1 mRNA were not statisti-
cally significantly different between the SP142-based cate-
gorical value (IC ≥ 1 versus IC < 1) [51]. In addition, another 
study reported that the protein expressional level of PD-L1 
in tumor and immune cells using SP142 assay was signifi-
cant lower than in other assays [52]. Association between 
SP142-detected PD-L1 expression on immune cells and PD-
L1 mRNA level should be further evaluated and may vary 
according to tumor/anatomic site as well.
Further genomic analyses elucidated that multiple 
immune-related genes were enriched in SP142 PD-L1-pos-
itive tumors. By generating a SP142 signature, we were able 
to classify TNBC tumors from additional datasets that had 
not had PD-L1 IHC classification, thus showing that our 
gene signature classification provided meaningful prog-
nostic information on multiple TNBC cohorts. In addition, 
we showed that on the 149 patient TNBC set, the PD-L1 
signature was a better prognostic factor than SP142 protein 
expression, or PD-L1 mRNA expression, noting that this is 
a training set exercise for the SP142 signature.
In addition, the SP142 signature was biologically vali-
dated using RNAseq data of TCGA-TNBC. This genomic 
study showed that the SP142 signature was correlated with 
lymphocyte-infiltration signature but not associated with 
TMB or neoantigen count, indicating that immunogenicity 
of TNBC arises mainly from lymphocytes-infiltrated micro-
environment. In addition, TNBCs with high SP142 signature 
exhibit increased expression of many other immune gene 
signatures compared to those with low-SP142 signature. Our 
findings are consistent with a prior study showing that the 
rate of high TMB tumors in TNBC is less than 10%, while 
the frequency of high T cell-inflamed TNBC samples is 
about 50% [2]. Collectively, our data indicates that increased 
level of lymphocyte infiltration is a major factor contributing 
to SP142 PD-L1 positivity in TNBC.
A hypothesis based upon the SP142 signature is the abil-
ity to distinguish TNBC patients that are likely to respond to 
combined ICIs and chemotherapy, and to do so objectively 
and in a quantitative fashion. Because a prior study sug-
gested that a T cell-inflamed gene signature might be poten-
tial biomarker responding to pembrolizumab in TNBC [2], 
investigating the SP142 signature as a predictive biomarker 
for PD-1/PD-L1 inhibitors is a promising future study.
This line of investigation is further strengthened by our 
evaluation of the SP142 signature in urothelial carcinoma, 
and melanoma cohorts, in which the patients were treated 
with ICIs. In metastatic urothelial carcinoma, the SP142 sig-
nature was associated with CR to atezolizumab and corre-
lated with the level of PD-L1 expression on immune cells. In 
both cohorts, continuous or categorical SP142 signature was 
associated with a better survival outcome; however, we note 
the use of the top one-third of SP142 scores to differentiate 
survival in urothelial carcinoma, as opposed to the top two-
thirds used in TNBC and melanoma. This is likely attribut-
able to differences in biology among various malignancies. 
Nonetheless, these findings suggest that the SP142 signature 
may be a valuable biomarker for ICI response in TNBC as 
well as other cancers, however, tumor type specific cutpoints 
may be required for optimal implementation.
Clinically, we recognized that PD-L1-positive TNBCs 
tended to have a better RFS than PD-L1-negative TNBC. 
The positive result showing PD-L1-positivity detected by 
standardized SP142 assay as a strong predictor for pCR in 
early TNBC [11] supports the notion that PD-L1 positivity 
on intra-tumoral immune cells is a favorable prognostic fac-
tor. It is known that an increment of pCR often correlates 
with better survival outcome in TNBC [53], suggesting that 
patients with SP142 PD-L1 expression might have a better 
outcome than those without expression; further analyses are 
needed to confirm this hypothesis.
These results demonstrate potential clinical value of the 
SP142 signature for pCR and survival in TNBCs, with the 
important implication that a high SP142 signature is asso-
ciated with a higher likelihood of response to chemother-
apy based on the neoadjuvant and adjuvant cohorts tested 
(Fig. 3a–d). Taken together, our survival analyses suggest 
consistently that the subjects identified by SP142 PD-L1 
assay, or SP142 gene signature, have a more favorable 
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prognosis among TNBC patients. Consistent with our 
results, a body of evidence already showed that high TIL-
tumors have better outcome in TNBC [54–56].
A major caveat of our study is that we evaluated PD-L1 
expression using TMA. Since the SP142 system evaluates 
PD-L1 expression on immune cells, contiguous peritu-
moral stroma could be investigated using the whole slide, 
but not on TMAs. Core extraction for TMAs focuses pri-
marily on invasive tumor components with a criteria of 
high cellularity (> 80%), making it possible that peritu-
moral stroma might not be fully evaluated in some cases, 
thereby increasing the potential for false negative cases in 
our study. This is a potential reason why our PD-L1 posi-
tive rate of 29% may be lower than published atezolizumab 
studies, which showed the rate as 41% in metastatic [5] or 
56% in early TNBC [11]. Nevertheless, the PD-L1+ sam-
ples identified in this study represent true positive cases in 
this context, thus our findings likely reflect genuine char-
acteristics of those tumors. Given that the primary goal of 
this study was to explore the biological and clinical traits 
of SP142+ TNBC, validating the true clinical utility of 
SP142 PD-L1 expression or SP142 genomic signature is 
beyond the scope of this study, but clearly the next step 
for this signature.
In conclusion, we provide multi-faceted evidence that 
SP142 PDL1+ TNBC have immuno-genomic features 
characterized as highly lymphocyte-infiltrated and a rela-
tively favorable survival amid TNBC. In addition, SP142 
genomic signature might provide information to identify 
immunogenic tumors making up as much as two-thirds 
of TNBC. These results enhance our understanding about 
immunogenicity of TNBC and lay the groundwork for fur-
ther studies integrating IHC and gene expression immune 
information for selecting patients to receive PD-1/PD-L1 
target therapies.
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